Passive Immunotherapeutics for Select Agents
Passive Immunotherapeutics for Select Agents
批准号:
7649817
负责人:
Clarence J. Peters
金额:
$26.93万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
Active immunityAnimal ModelAntibodiesAntiviral AgentsB lymphocyte immortalizationBiological AssayCaviaCell LineCellsClinicalDataDiseaseEpitopesEvaluationFeverFreezingGoalsGuanosine MonophosphateHamstersHumanHuman Herpesvirus 4HybridomasImmunotherapeutic agentInfectionJunin virusLaboratoriesLimesMonoclonal AntibodiesNipah VirusNon-Hodgkin&aposs LymphomaPassive ImmunotherapyPathogen detectionPeripheral Blood LymphocyteProductionProphylactic treatmentRabiesReagentRecombinant ProteinsRift Valley fever virusRoleSafetyScreening procedureSerologicalSerumSmallpox VirusesSpecificityTestingTherapeuticTissuesUnited States Food and Drug AdministrationVaccinesVirusVirus DiseasesWorkWorld Health Organizationbasehuman monoclonal antibodiesimmunoreactivityimprovedneutralizing antibodypathogenpreventrespiratorysuccessuptake
中文摘要
暴露后的预防和治疗是管理新出现的病毒的重大挑战
疾病。疫苗在暴露后预防中可能有帮助,在这种情况下,代理复制s10wty或最初
与世隔绝在外围。然而,在大多数情况下,主动免疫不会出现在时间帧中
疾病是可以预防或改善的。被动免疫疗法已经有了既定的记录
在狂犬病感染的管理方面。呼吸道合胞病毒和天花病毒。除极少数情况外
抗体与宿主组织发生交叉反应导致疾病或增强病毒吸收以加速
感染的进展,被动免疫治疗的效果是特异的。抗病毒药物已用于
在许多感染中取得成功,有效化合物的保存库无疑将得到改善;
但不管怎样。被动免疫治疗将继续是重要的主要或补充路线
防守。被动免疫治疗试剂包括恢复期血清和单抗。
(单抗)。单抗具有明确的反应性和特异性。和增强的安全配置文件。
通过以前在世卫组织实验室网络范围内病原体检测方面的工作,我们可以
从感染高危病原体康复的受害者的外周血淋巴细胞(PBL)。我们
已经确定PBL可以冷冻保存,并在切除几个月后用于融合,仅在
免疫球蛋白产量损失微乎其微。这个Trans-RCE项目将利用人类PBL并直接与
高效人杂交瘤融合配对细胞系(MFP?2)及EB病毒永生化B细胞的研究
和CpG,然后与HMMA2.5融合伙伴细胞系进行融合,产生完全人的单抗
(FhMAB)专用于三种选定的制剂:Junin病毒、Nipah病毒和Rift。瓦希热病毒。选择
靶点是基于表明被动免疫疗法的潜在治疗作用和可用性的数据
具有良好特征的临床材料。在以下背景下对MFP-2进行了有限的评估
美国食品和药物管理局的一名情报人员。此外,双方还建立了商业关系,目标是
生产用于治疗非霍奇金淋巴瘤的GMP级fhMAb。这些因素将使过渡成为可能
具有抗病毒活性的fhMAb从动物模型到临床应用。具体目标包括:1.建立
用于筛选恢复期供者血清和人杂交瘤上清液的血清学试验;
鉴定供体血清和PBL,并产生人杂交瘤细胞系;以及3.检测中和抗体
动物模型中的保护性活动。
英文摘要
Post exposure prophylaxis and treatment are aitical challenges in the management of emerging viral
diseases. Vaccines may be helpful in post exposure prophylaxis where agents replicate s10wty or are initially
sequestered in the periphery. However, in most instances, active immunity does not occur in a lime frame
wherein disease can be prevented or ameliorated. Passive immunotherapy has an established track record
in management of infections with rabies. respiratory syncytial, and variola viruses. Except in rare instances
where antibodies cross react with host tissues to cause disease or enhance virus uptake to accelerate
progression of infection, the effects of passive immunotherapy are specific. Anlivirals have been used with
success in many infections, and the repertoire of effective compounds will undoubtedly improve;
nonetheless. passive immunotherapy will continue to be a significant primary or complementary line of
defense. Reagents for passive immunotherapy include both convalescent serum and monoclonal antibodies
(MAbs). MAbs have the advantages of defined reactivity and specificity. and enhanced safety profiles.
Through previous work in pathogen detection in context of the WHO laboratory network we have access
to peripheral blood lymphocytes (PBL) from victims recovered from infection with high.risk pathogens. We
have established that PBL can be stored frozen and used for fusion several months after ootlection with only
insignificant loss of Ig production. This Trans-RCE project will exploit human PBL and direct fusion with an
effICient human hybridoma fusion partner cell line (MFP¿2), as well as immortalization of B cells using EBV
and CpG followed by e1eeuofusion with a HMMA2.5 fusion partner cell line to produce fully human MAbs
(fhMAB) SpecifIC for three select agents: Junin virus, Nipah virus, and Rift. VaHey fever virus. The choice of
targets is based on data indicating a potential therapeutic role for passive immunotherapy and the avaHability
well-characterized clinical materials. A limited evaluation of MFP-2 has been oonducted in the context of
ding an INO with the FDA. Furthennore, a commercial relationship has been established with the goal of
producing GMP grade fhMAbs for treatment of non-Hodgkin lymphomas. These factors will enable transition
of fhMAbs with antiviral activity from animal models to clinical use. Specific aims include: 1. Establish
serologic assays for screening of convalescent donor sera and human hybridoma supernatants; 2.
Characterize donor sera and PBl, and generate human hybridoma lines; and 3. Test neutraliZing fhMAbs for
protective activity in animal models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BSL4 Core
-
批准号:7649747
-
项目类别:
-
资助金额:$19.1万
-
财政年份:2008
-
负责人:Clarence J. Peters
-
依托单位:
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
-
批准号:7623932
-
项目类别:
-
资助金额:$128.26万
-
财政年份:2008
-
负责人:Clarence J. Peters
-
依托单位:
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
-
批准号:7860454
-
项目类别:
-
资助金额:$43.11万
-
财政年份:2008
-
负责人:Clarence J. Peters
-
依托单位:
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
-
批准号:7455452
-
项目类别:
-
资助金额:$84.0万
-
财政年份:2008
-
负责人:Clarence J. Peters
-
依托单位:
Infectious Diseases From Nature: Mclaughlin Symposium
-
批准号:6760836
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2004
-
负责人:Clarence J. Peters
-
依托单位:
Rift Valley Fever Virus MP-12 Vaccine Completion
-
批准号:6845770
-
项目类别:
-
资助金额:$565.31万
-
财政年份:2004
-
负责人:Clarence J. Peters
-
依托单位:
EPIZOOTIOLOGY OF MACHUPO VIRUS IN BOLIVIA
-
批准号:6201308
-
项目类别:
-
资助金额:$12.49万
-
财政年份:1999
-
负责人:Clarence J. Peters
-
依托单位:
EPIZOOTIOLOGY OF MACHUPO VIRUS IN BOLIVIA
-
批准号:6216439
-
项目类别:
-
资助金额:$12.49万
-
财政年份:1999
-
负责人:Clarence J. Peters
-
依托单位:
EPIZOOTIOLOGY OF MACHUPO VIRUS IN BOLIVIA
-
批准号:6100086
-
项目类别:
-
资助金额:$12.49万
-
财政年份:1998
-
负责人:Clarence J. Peters
-
依托单位:
EPIZOOTIOLOGY OF MACHUPO VIRUS IN BOLIVIA
-
批准号:6235505
-
项目类别:
-
资助金额:$12.01万
-
财政年份:1997
-
负责人:Clarence J. Peters
-
依托单位:
EPIZOOTIOLOGY OF MACHUPO VIRUS IN BOLIVIA
-
批准号:5206010
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Clarence J. Peters
-
依托单位:--
海外基金